ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: SA-PO1090

Chronic Treatment with Tadalafil Prevented Renal Dysfunction and Hypertension Caused by High Salt Intake and Preserved Serum SDF-1α Levels in Dahl Salt-Sensitive Rats

Session Information

Category: Hypertension

  • 1102 Hypertension: Basic and Experimental - Renal Causes and Consequences

Authors

  • Tomita, Natsumi, Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya, Japan
  • Hotta, Yuji, Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya, Japan
  • Naiki-Ito, Aya, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan
  • Kataoka, Tomoya, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan
  • Maeda, Yasuhiro, Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya, Japan
  • Takahashi, Satoru, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan
  • Kimura, Kazunori, Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya, Japan
Background

Phosphodiesterase inhibitors (PDE5is) are reported to prevent renal damage and/or blood pressure (BP) elevation in an ischemic-reperfusion model. It is uncertain whether PDE5is are effective against salt sensitive hypertension; thus, we investigated the effects of a PDE5i, tadalafil, on hypertension and renal dysfunction induced by high salt intake using an animal model.

Methods

Eight-week-old male Dahl salt-sensitive rats were divided into three groups (n=6); normal salt (NS), high salt (8% NaCl-included diet; HS), and high salt and tadalafil treatment (10 mg/kg/day, p.o; Tad). Blood urea nitrogen, serum creatinine (SCre), proteinuria, and BP were evaluated at 0, 4, and 8 weeks. The kidney was extracted at 8 weeks and PAS staining was performed. Serum stromal cell-derived factor 1 (SDF-1)-α level, which is associated with the repair of vascular endothelial injury, was also evaluated at the 8 week timepoint.

Results

BP and proteinuria significantly increased in the HS group (P<0.01), while tadalafil treatment attenuated proteinuria and BP elevation at 8 weeks (P<0.01 vs. HS) (Fig.1). While SCre did not increase in the Tad group, it increased in the HS group (P<0.05) at 8 weeks. Glomerulosclerosis and atherosclerosis in the kidney also increased in the HS group (P<0.01), although they were suppressed in the Tad group (P<0.01 vs. HS). Serum SDF-1α level significantly decreased (P<0.01) in the HS group and normalized in the Tad group (P<0.05 vs. HS).

Conclusion

Tadalafil may be an effective treatment for salt-sensitive hypertension, atherosclerosis, and renal dysfunction and maintains SDF-1α level.

Fig.1 Variations in systolic blood pressure (A) and urinary protein to creatinine ratio (B) in each group (n=6). ANOVA and Bonferroni-type multiple t-test. * P<0.01 vs. NS, # P<0.01 vs. HS